Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy

The Lancet

Volumn 390, Issue 10105, 2017, Pages 1888-1917

  Levin, Adeera ^a   Tonelli, Marcello ^b   Bonventre, Joseph ^c   Coresh, Josef ^d,e   Donner, Jo Ann ^f   Fogo, Agnes B ^g   Fox, Caroline S ^h   Gansevoort, Ron T ⁱ   Heerspink, Hiddo J L ⁱ   Jardine, Meg ^j,k   Kasiske, Bertram ^l,m   Köttgen, Anna ⁿ   Kretzler, Matthias ^o   Levey, Andrew S ^p   Luyckx, Valerie A ^q   Mehta, Ravindra ^r   Moe, Orson ^s   Obrador, Gregorio ^t   Pannu, Neesh ^u   Parikh, Chirag R ^v,w   Perkovic, Vlado ^j,x   Pollock, Carol ^y   Stenvinkel, Peter ^z   Tuttle, Katherine R ^aa   Wheeler, David C ^ab   Eckardt, Kai Uwe ^ac   Adu, Dwomoa ^ad   Agarwal, Sanjay Kumar ^ad   Alrukhaimi, Mona ^ad   Anders, Hans Joachim ^ad   Ashuntantang, Gloria ^ad   Basnet, Shakti ^ad   Bello, Aminu K ^ad   Chailimpamontree, Worawon ^ad   Correa Rotter, Ricardo ^ad   Craig, Jonathan ^ad   Douthat, Walter G ^ad   Feldman, Harold I ^ad   Ganji, Mohammad Reza ^ad   Garcia Garcia, Guillermo ^ad   Gharbi, Mohammed Benghanem ^ad   Harris, David C ^ad   Jha, Vivekanand ^ad   Johnson, David W ^ad   Kazancioglu, Rumeyza ^ad   Langham, Robyn ^ad   Liu, Zhi Hong ^ad   Massy, Ziad A ^ad   Nangaku, Masaomi ^ad   Nelson, Robert G ^ad   O'Donoghue, Donal ^ad   Okpechi, Ikechi ^ad   Pecoits Filho, Roberto ^ad   Powe, Neil R ^ad   Remuzzi, Giuseppe ^ad   Roberts, Charlotte ^ad   Rossert, Jerome ^ad   Sola, Laura ^ad   Stengel, Benedicte ^ad   M, Ernest K Sumaili ^ad   Suzuki, Yusuke ^ad   Tanaka, Tetsuhiro ^ad   Tatiyanupanwong, Sajja ^ad   Thomas, Bernadette ^ad   Uhlig, Katrin ^ad   Walker, Robert ^ad   White, Sarah L ^ad   Wiecek, Andrzej ^ad   Yang, Chih Wei ^ad   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f International Society of Nephrology   (Belgium)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^j GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^k Department of Microbiology and Infectious Diseases   (Australia)

^l HENNEPIN COUNTY MEDICAL CENTER   (United States)

^m UNIVERSITY OF MINNESOTA   (United States)

ⁿ UNIVERSITY OF FREIBURG   (Germany)

^o UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^p TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF ZURICH   (Switzerland)

^r UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^s UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^t UNIVERSIDAD PANAMERICANA   (Mexico)

^u UNIVERSITY OF ALBERTA   (Canada)

^v YALE UNIVERSITY   (United States)

^w VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^x UNIVERSITY OF SYDNEY   (Australia)

^y UNIVERSITY OF SYDNEY   (Australia)

^z KAROLINSKA INSTITUTE   (Sweden)

^aa UNIVERSITY OF WASHINGTON   (United States)

^ab UNIVERSITY COLLEGE LONDON   (United Kingdom)

^ac UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^ad NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE KIDNEY FAILURE; CHRONIC KIDNEY FAILURE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE SURVEILLANCE; GLOBAL HEALTH; HEALTH CARE POLICY; HEREDITY; HUMAN; MOLECULAR PATHOLOGY; PATIENT ADVOCACY; PATIENT CARE; PRIORITY JOURNAL; RESEARCH PRIORITY; REVIEW; RISK FACTOR; TREATMENT PLANNING; DISEASE EXACERBATION; DISEASE MANAGEMENT; DRUG DEVELOPMENT; GENETIC PREDISPOSITION; HEALTH CARE PLANNING; ORGANIZATION; PRACTICE GUIDELINE; PRECLINICAL STUDY;

ACUTE KIDNEY INJURY; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; DISEASE MANAGEMENT; DISEASE PROGRESSION; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; GENETIC PREDISPOSITION TO DISEASE; GLOBAL HEALTH; HEALTH PRIORITIES; HUMANS; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 85018660023     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30788-2     Document Type: Review

References (227)

1. Eckardt, K-U, Coresh, J, Devuyst, O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 382 (2013), 158–169.
2. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1545–1602.
3. Couser, WG, Remuzzi, G, Mendis, S, Tonelli, M, The contribution of chronic kidney disease to the global burden of major non-communicable diseases. Kidney Int 80 (2011), 1258–1270.
4. Levey, AS, de Jong, PE, Coresh, J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 80 (2011), 17–28.
5. Chronic Kidney Disease Prognosis Consortium, Matsushita, K, van der Velde, M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality: a collaborative meta-analysis. Lancet 375 (2010), 2073–2081.
6. Liyanage, T, Ninomiya, T, Jha, V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385 (2015), 1975–1982.
7. Jha, V, Garcia-Garcia, G, Iseki, K, et al. Chronic kidney disease: global dimension and perspectives. Lancet 382 (2013), 260–272.
8. Luyckx, VA, Naicker, S, McKee, M, Equity and economics of kidney disease in sub-Saharan Africa. Lancet 382 (2013), 103–104.
9. Khatib, R, McKee, M, Shannon, H, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet 387 (2016), 61–69.
10. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3 (2013), 1–150.
11. Benghanem Gharbi, M, Elseviers, M, Zamd, M, et al. Chronic kidney disease, hypertension, diabetes, and obesity in the adult population of Morocco: how to avoid ‘over’- and ‘under’-diagnosis of CKD. Kidney Int 89 (2016), 1363–1371.
12. Coresh, J, Selvin, E, Stevens, LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 298 (2007), 2038–2047.
13. Murphy, D, McCulloch, CE, Lin, F, et al. Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med 165 (2016), 473–481.
14. Hill, NR, Fatoba, ST, Oke, JL, et al. Global prevalence of chronic kidney disease—a systematic review and meta-analysis. PLoS One, 11, 2016, e0158765.
15. Chen, N, Wang, W, Huang, Y, et al. Community-based study on CKD subjects and the associated risk factors. Nephrol Dial Transplant 24 (2009), 2117–2123.
16. Kramer, H, Palmas, W, Kestenbaum, B, et al. Chronic kidney disease prevalence estimates among racial/ethnic groups: the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol 3 (2008), 1391–1397.
17. Grams, ME, Juraschek, SP, Selvin, E, et al. Trends in the prevalence of reduced GFR in the United States: a comparison of creatinine- and cystatin C—based estimates. Am J Kidney Dis 62 (2013), 253–260.
18. Go, AS, Chertow, GM, Fan, D, McCulloch, CE, Hsu, C, Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004), 1296–1305.
19. Tonelli, M, Muntner, P, Lloyd, A, et al., for the Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380 (2012), 807–814.
20. London, R, Solis, A, Goldberg, GA, Wade, S, Ryu, S, Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis 40 (2002), 539–548.
21. GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1603–1658.
22. Weber, C, Beaulieu, M, Djurdjev, O, et al. Towards rational approaches of health care utilization in complex patients: an exploratory randomized trial comparing a novel combined clinic to multiple specialty clinics in patients with renal disease-cardiovascular disease-diabetes. Nephrol Dial Transplant 27:suppl 3 (2012), iii104–iii110.
23. Lee, H, Manns, B, Taub, K, et al. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis 40 (2002), 611–622.
24. Parving, HH, Brenner, BM, McMurray, JJV, et al., for the ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367 (2012), 2204–2213.
25. de Zeeuw, D, Akizawa, T, Audhya, P, et al., for the BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369 (2013), 2492–2503.
26. Mann, JF, Green, D, Jamerson, K, et al., for the ASCEND Study Group. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21 (2010), 527–535.
27. Fried, LF, Emanuele, N, Zhang, JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369 (2013), 1892–1903.
28. Pfeffer, MA, Burdmann, EA, Chen, CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361 (2009), 2019–2032.
29. Walz, G, Budde, K, Mannaa, M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363 (2010), 830–840.
30. UN. Sustainable development goals. http://www.un.org/sustainabledevelopment/sustainable-development-goals/, 2015 (accessed Oct 5, 2016).
31. Mills, KT, Xu, Y, Zhang, W, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int 88 (2015), 950–957.
32. Hill, NR, Fatoba, ST, Oke, JL, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One, 11, 2016, e0158765.
33. Brück, K, Stel, VS, Gambaro, G, et al. CKD prevalence varies across the European general population. J Am Soc Nephrol 27 (2016), 2135–2147.
34. Brück, K, Jager, KJ, Dounousi, E, et al. Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review. Nephrol Dial Transplant, 31, 2016, 680.
35. Parrinello, CM, Grams, ME, Couper, D, et al. Recalibration of blood analytes over 25 years in the atherosclerosis risk in communities study: impact of recalibration on chronic kidney disease prevalence and incidence. Clin Chem 61 (2015), 938–947.
36. Matsushita, K, Selvin, E, Bash, LD, Astor, BC, Coresh, J, Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation as compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis 55 (2010), 648–659.
37. Matsushita, K, Mahmoodi, BK, Woodward, M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 307 (2012), 1941–1951.
38. Witte, EC, Lambers Heerspink, HJ, de Zeeuw, D, Bakker, SJL, de Jong, PE, Gansevoort, R, First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 20 (2009), 436–443.
39. Selvin, E, Juraschek, SP, Eckfeldt, J, Levey, AS, Inker, LA, Coresh, J, Within-person variability in kidney measures. Am J Kidney Dis 61 (2013), 716–722.
40. WHO. International Classification of Diseases version 11.2016. http://www.who.int/classifications/icd/en/ (accessed Oct 2, 2016).
41. Grams, ME, Rebholz, C, MacMahon, B, et al. Identification of incident CKD stage 3 in research studies. Am J Kidney Dis 64 (2014), 214–221.
42. Rebholz, CM, Coresh, J, Ballew, SH, et al. Kidney failure and ESRD in the atherosclerosis risk in communities (ARIC) study: comparing ascertainment of treated and untreated kidney failure in a cohort study. Am J Kidney Dis 66 (2015), 231–239.
43. Zhang, L, Long, J, Jiang, W, et al. Trends in chronic kidney disease in China. N Engl J Med 375 (2016), 905–906.
44. Carrero, JJ, Grams, ME, Sang, Y, et al. Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. Kidney Int 91 (2017), 244–251.
45. Agarwal, SK, Wruck, L, Quibrera, M, et al. Temporal trends in hospitalization for acute decompensated heart failure in the United States, 1998–2011. Am J Epidemiol 183 (2016), 462–470.
46. Venkat-Raman, G, Tomson, CR, Gao, Y, et al. New primary renal diagnosis codes for the ERA-EDTA. Nephrol Dial Transplant 27 (2012), 4414–4419.
47. Levey, AS, Stevens, LA, Schmid, CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
48. Diamantidis, CJ, Becker, S, Health information technology (IT) to improve the care of patients with chronic kidney disease (CKD). BMC Nephrol, 15, 2014, 7.
49. Drawz, PE, Archdeacon, P, McDonald, CJ, et al. CKD as a model for improving chronic disease care through electronic health records. Clin J Am Soc Nephrol 10 (2015), 1488–1499.
50. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1459–1544.
51. Soderland, P, Lovekar, S, Weiner, DE, Brooks, DR, Kaufman, JS, Chronic kidney disease associated with environmental toxins and exposures. Adv Chronic Kidney Dis 17 (2010), 254–264.
52. Correa-Rotter, R, Wesseling, C, Johnson, RJ, CKD of unknown origin in Central America: the case for a Mesoamerican nephropathy. Am J Kidney Dis 63 (2014), 506–520.
53. Glaser, J, Lemery, J, Rajagopalan, B, et al. Climate change and the emergent epidemic of CKD from heat stress in rural communities: the case for heat stress nephropathy. Clin J Am Soc Nephrol 11 (2016), 1472–1483.
54. Johnson, RJ, Stenvinkel, P, Jensen, T, et al. Metabolic and kidney diseases in the setting of climate change, water shortage, and survival factors. J Am Soc Nephrol 27 (2016), 2247–2256.
55. Weaver, VM, Fadrowski, JJ, Jaar, BG, Global dimensions of chronic kidney disease of unknown etiology (CKDu): a modern era environmental and/or occupational nephropathy?. BMC Nephrol, 16, 2015, 145.
56. Debelle, FD, Vanherweghem, JL, Nortier, JL, Aristolochic acid nephropathy: a worldwide problem. Kidney Int 74 (2008), 158–169.
57. Grollman, AP, Aristolochic acid nephropathy: harbinger of a global iatrogenic disease. Environ Mol Mutagen 54 (2013), 1–7.
58. Bui-Klimke, T, Wu, F, Evaluating weight of evidence in the mystery of Balkan endemic nephropathy. Risk Anal 34 (2014), 1688–1705.
59. Yang, L, Su, T, Li, X-M, et al. Aristolochic acid nephropathy: variation in presentation and prognosis. Nephrol Dial Transplant 27 (2012), 292–298.
60. Kataria, A, Trasande, L, Trachtman, H, The effects of environmental chemicals on renal function. Nat Rev Nephrol 11 (2015), 610–625.
61. Tuttle, KR, Bakris, GL, Bilous, RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis 64 (2014), 510–533.
62. Stenvinkel, P, Zoccali, C, Ikizler, TA, Obesity in CKD—what should nephrologists know?. J Am Soc Nephrol 24 (2013), 1727–1736.
63. Jun, M, Hemmelgarn, BR, Strategies for BP control in developing countries and effects on kidney function. Clin J Am Soc Nephrol 11 (2016), 932–934.
64. Jafar, TH, Allen, JC, Jehan, I, et al. Health education and general practitioner training in hypertension management: long-term effects on kidney function. Clin J Am Soc Nephrol 11 (2016), 1044–1053.
65. James, PA, Oparil, S, Carter, BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311 (2014), 507–520.
66. ACCORD Study Group. Nine-year effects of 3·7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care 39 (2016), 701–708.
67. Zoungas, S, Chalmers, J, Neal, B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 371 (2014), 1392–1406.
68. Pannu, N, Nadim, MK, An overview of drug-induced acute kidney injury. Crit Care Med 36:suppl (2008), S216–S223.
69. Mehta, RL, Burdmann, EA, Cerdá J, et al. Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 Global Snapshot: a multinational cross-sectional study. Lancet 387 (2016), 2017–2025.
70. Rhone, ET, Carmody, JB, Swanson, JR, Charlton, JR, Nephrotoxic medication exposure in very low birth weight infants. J Matern Fetal Neonatal Med 27 (2014), 1485–1490.
71. Menon, S, Kirkendall, ES, Nguyen, H, Goldstein, SL, Acute kidney injury associated with high nephrotoxic medication exposure leads to chronic kidney disease after 6 months. J Pediatr 165 (2014), 522–527.
72. Lazarus, B, Chen, Y, Wilson, FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 176 (2016), 238–246.
73. Moledina, DG, Perazella, MA, Proton pump inhibitors and CKD. J Am Soc Nephrol 27 (2016), 2926–2928.
74. Radhakrishnan, J, Perazella, MA, Drug-induced glomerular disease: attention required!. Clin J Am Soc Nephrol 10 (2015), 1287–1290.
75. Luyckx, VA, Nephrotoxicity of alternative medicine practice. Adv Chronic Kidney Dis 19 (2012), 129–141.
76. De Smet, PA, Herbal medicine in Europe—relaxing regulatory standards. N Engl J Med 352 (2005), 1176–1178.
77. Richardson, K, Ananou, A, Lafortune, L, Brayne, C, Matthews, FE, Variation over time in the association between polypharmacy and mortality in the older population. Drugs Aging 28 (2011), 547–560.
78. Tinetti, ME, Bogardus, ST Jr, Agostini, JV, Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 351 (2004), 2870–2874.
79. Gnjidic, D, Le Couteur, DG, Pearson, SA, et al. High risk prescribing in older adults: prevalence, clinical and economic implications and potential for intervention at the population level. BMC Public Health, 13, 2013, 115.
80. Frazier, SC, Health outcomes and polypharmacy in elderly individuals: an integrated literature review. J Gerontol Nurs 31 (2005), 4–11.
81. Keddis, MT, Rule, AD, Nephrolithiasis and loss of kidney function. Curr Opin Nephrol Hypertens 22 (2013), 390–396.
82. Scales, CD Jr, Tasian, GE, Schwaderer, AL, Goldfarb, DS, Star, RA, Kirkali, Z, Urinary stone disease: advancing knowledge, patient care, and population health. Clin J Am Soc Nephrol 11 (2016), 1305–1312.
83. López, M, Hoppe, B, History, epidemiology and regional diversities of urolithiasis. Pediatr Nephrol 25 (2010), 49–59.
84. Taylor, EN, Stampfer, MJ, Curhan, GC, Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol 15 (2004), 3225–3232.
85. Lameire, NH, Bagga, A, Cruz, D, et al. Acute kidney injury: an increasing global concern. Lancet 382 (2013), 170–179.
86. Kayange, NM, Smart, LR, Tallman, JE, et al. Kidney disease among children in sub-Saharan Africa: a systematic review. Pediatr Res 77 (2015), 272–281.
87. Jha, V, Prasad, N, CKD and infectious diseases in Asia Pacific: challenges and opportunities. Am J Kidney Dis 68 (2016), 148–160.
88. UNAIDS. Global AIDS Update 2016. http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016, 2016 (accessed Sept 11, 2016).
89. Rosenberg, AZ, Naicker, S, Winkler, CA, Kopp, JB, HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment. Nat Rev Nephrol 11 (2015), 150–160.
90. Lucas, GM, Ross, MJ, Stock, PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 59 (2014), e96–e138.
91. White, NJ, Pukrittayakamee, S, Hien, TT, Faiz, MA, Mokuolu, OA, Dondorp, AM, Malaria. Lancet 383 (2014), 723–735.
92. Ehrich, JH, Eke, FU, Malaria-induced renal damage: facts and myths. Pediatr Nephrol 22 (2007), 626–637.
93. Siriwardhana, EA, Perera, PA, Sivakanesan, R, Abeysekara, T, Nugegoda, DB, Jayaweera, JA, Dehydration and malaria augment the risk of developing chronic kidney disease in Sri Lanka. Indian J Nephrol 25 (2015), 146–151.
94. WHO. Global Tuberculosis Report 2015, 2015, World Health Organization, Geneva.
95. Daher Ede, F, da Silva, GB Jr, Barros, EJ, Renal tuberculosis in the modern era. Am J Trop Med Hyg 88 (2013), 54–64.
96. de Oliveira, JL, da Silva, GB Jr, Daher, Ede F, Tuberculosis-associated chronic kidney disease. Am J Trop Med Hyg 84 (2011), 843–844.
97. Hoy, WE, White, AV, Dowling, A, et al. Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life. Kidney Int 81 (2012), 1026–1032.
98. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (2015), 743–800.
99. Gupta, A, Quigg, RJ, Glomerular diseases associated with hepatitis B and C. Adv Chronic Kidney Dis 22 (2015), 343–351.
100. Azmi, AN, Tan, SS, Mohamed, R, Hepatitis C and kidney disease: an overview and approach to management. World J Hepatol 7 (2015), 78–92.
101. Barsoum, RS, Esmat, G, El-Baz, T, Human schistosomiasis: clinical perspective: review. J Adv Res 4 (2013), 433–444.
102. de Jong, F, Monuteaux, MC, van Elburg, RM, Gillman, MW, Belfort, MB, Systematic review and meta-analysis of preterm birth and later systolic blood pressure. Hypertension 59 (2012), 226–234.
103. Mu, M, Wang, SF, Sheng, J, et al. Birth weight and subsequent blood pressure: a meta-analysis. Arch Cardiovasc Dis 105 (2012), 99–113.
104. Whincup, PH, Kaye, SJ, Owen, CG, et al. Birth weight and risk of type 2 diabetes: a systematic review. JAMA 300 (2008), 2886–2897.
105. Cnattingius, S, Villamor, E, Lagerros, YT, Wikström, AK, Granath, F, High birth weight and obesity—a vicious circle across generations. Int J Obes (Lond) 36 (2012), 1320–1324.
106. Luyckx, VA, Brenner, BM, Birth weight, malnutrition and kidney-associated outcomes—a global concern. Nat Rev Nephrol 11 (2015), 135–149.
107. Selewski, DT, Charlton, JR, Jetton, JG, et al. Neonatal acute kidney injury. Pediatrics 136 (2015), e463–e473.
108. Mammen, C, Al Abbas, A, Skippen, P, et al. Long-term risk of CKD in children surviving episodes of acute kidney injury in the intensive care unit: a prospective cohort study. Am J Kidney Dis 59 (2012), 523–530.
109. Vikse, BE, Pre-eclampsia and the risk of kidney disease. Lancet 382 (2013), 104–106.
110. Paauw, ND, Luijken, K, Franx, A, Verhaar, MC, Lely, AT, Long-term renal and cardiovascular risk after preeclampsia: towards screening and prevention. Clin Sci 130 (2016), 239–246.
111. Damm, P, Houshmand-Oeregaard, A, Kelstrup, L, Lauenborg, J, Mathiesen, ER, Clausen, TD, Gestational diabetes mellitus and long-term consequences for mother and offspring: a view from Denmark. Diabetologia 59 (2016), 1396–1399.
112. Kanguru, L, Bezawada, N, Hussein, J, Bell, J, The burden of diabetes mellitus during pregnancy in low- and middle-income countries: a systematic review. Glob Health Action, 7, 2014, 23987.
113. Pannu, N, Bidirectional relationships between acute kidney injury and chronic kidney disease. Curr Opin Nephrol Hypertens 22 (2013), 351–356.
114. Chawla, LS, Eggers, PW, Star, RA, Kimmel, PL, Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 371 (2014), 58–66.
115. Coca, SG, Singanamala, S, Parikh, CR, Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 81 (2012), 442–448.
116. Hsu, CY, Ordoñez, JD, Chertow, GM, Fan, D, McCulloch, CE, Go, AS, The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 74 (2008), 101–107.
117. Huang, TM, Wu, VC, Young, GH, et al. Preoperative proteinuria predicts adverse renal outcomes after coronary artery bypass grafting. J Am Soc Nephrol 22 (2011), 156–163.
118. Grams, ME, Astor, BC, Bash, LD, Matsushita, K, Wang, Y, Coresh, J, Albuminuria and estimated glomerular filtration rate independently associate with acute kidney injury. J Am Soc Nephrol 21 (2010), 1757–1764.
119. James, MT, Hemmelgarn, BR, Wiebe, N, et al. Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet 376 (2010), 2096–2103.
120. Pannu, N, James, M, Hemmelgarn, BR, et al. Modification of outcomes after acute kidney injury by the presence of CKD. Am J Kidney Dis 58 (2011), 206–213.
121. Silver, SA, Wald, R, Improving outcomes of acute kidney injury survivors. Curr Opin Crit Care 21 (2015), 500–505.
122. Mehta, RL, Cerdá J, Burdmann, EA, et al. International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet 385 (2015), 2616–2643.
123. Perazella, MA, Coca, SG, Traditional urinary biomarkers in the assessment of hospital-acquired AKI. Clin J Am Soc Nephrol 7 (2012), 167–174.
124. Chawla, LS, Dommu, A, Berger, A, Shih, S, Patel, SS, Urinary sediment cast scoring index for acute kidney injury: a pilot study. Nephron Clin Pract 110 (2008), c145–c150.
125. Hemmett, J, Er, L, Chiu, HH, Cheung, C, Djurdjev, O, Levin, A, Time to revisit the problem of CIN? The low incidence of acute kidney injury with and without contrast in hospitalized patients: an observational cohort study. Can J Kidney Health Dis, 2, 2015, 38.
126. Kidney disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2 (2012), 1–138.
127. Silver, SA, Goldstein, SL, Harel, Z, et al. Ambulatory care after acute kidney injury: an opportunity to improve patient outcomes. Can J Kidney Health Dis, 2, 2015, 36.
128. O'Seaghdha, CM, Fox, CS, Genome-wide association studies of chronic kidney disease: what have we learned?. Nat Rev Nephrol 8 (2011), 89–99.
129. Vivante, A, Hildebrandt, F, Exploring the genetic basis of early-onset chronic kidney disease. Nat Rev Nephrol 12 (2016), 133–146.
130. Wuttke, M, Köttgen, A, Insights into kidney diseases from genome-wide association studies. Nat Rev Nephrol 12 (2016), 549–562.
131. Genovese, G, Friedman, DJ, Ross, MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329 (2010), 841–845.
132. Manrai, AK, Funke, BH, Rehm, HL, et al. Genetic misdiagnoses and the potential for health disparities. N Engl J Med 375 (2016), 655–665.
133. Fox, CS, Hall, JL, Arnett, DK, et al. Future translational applications from the contemporary genomics era. Circulation 131 (2015), 1715–1736.
134. Green, RC, Goddard, KAB, Jarvik, GP, et al. Clinical sequencing exploratory research consortium: accelerating evidence-based practice of genomic medicine. Am J Hum Genet 98 (2016), 1051–1066.
135. Jarvik, GP, Amendola, LM, Berg, JS, et al. Return of genomic results to research participants: the floor, the ceiling, and the choices in between. Am J Hum Genet 94 (2014), 818–826.
136. Tekola-Ayele, F, Rotimi, CN, Translational genomics in low and middle income countries: opportunities and challenges. Public Health Genomics 18 (2015), 242–247.
137. Lek, M, Karczewski, KJ, Minikel, EV, et al. Analysis of protein-coding genetic variation in 60 706 humans. Nature 536 (2016), 285–291.
138. Rehm, HL, Berg, JS, Brooks, LD, et al. ClinGen—the clinical genome resource. N Engl J Med 372 (2015), 2235–2242.
139. Chen, R, Shi, L, Hakenberg, J, et al. Analysis of 589 306 genomes identifies individuals resilient to severe Mendelian childhood diseases. Nat Biotechnol 34 (2016), 531–538.
140. Genomes Project Consortium, Auton, A, Brooks, LD, et al. A global reference for human genetic variation. Nature 526 (2015), 68–74.
141. Tzur, S, Rosset, S, Shemer, R, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128 (2010), 345–350.
142. Köttgen, A, Pattaro, C, Böger, CA, et al. Multiple new loci associated with kidney function and chronic kidney disease. Nat Genet 42 (2010), 376–384.
143. Böger, CA, Chen, MH, Tin, A, et al. CUBN is a gene locus for albuminuria. J Am Soc Nephrol 22 (2011), 555–570.
144. Böger, CA, Gorski, M, Li, M, et al. Association of eGFR-related loci identified by GWAS with incident CKD and ESRD. PLoS Genet, 7, 2011, e1002292.
145. Pattaro, C, Teumer, A, Gorski, M, et al. Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nat Commun, 7, 2016, 10023.
146. Wilkinson, MD, Dumontier, M, Aalbersberg, IJJ, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data, 3, 2016, 160018.
147. Welter, D, MacArthur, J, Morales, J, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res 42 (2014), D1001–D1006.
148. Margolis, R, Derr, L, Dunn, M, et al. The National Institutes of Health's Big Data to Knowledge (BD2K) initiative: capitalizing on biomedical big data. J Am Med Inform Assoc 21 (2014), 957–958.
149. Flannick, J, Florez, JC, Type 2 diabetes: genetic data sharing to advance complex disease research. Nat Rev Genet 17 (2016), 535–549.
150. MacArthur, DG, Manolio, TA, Dimmock, DP, et al. Guidelines for investigating causality of sequence variants in human disease. Nature 508 (2014), 469–476.
151. Amendola, LM, Dorschner, MO, Robertson, PD, et al. Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Res 25 (2015), 305–315.
152. Kao, WH, Klag, MJ, Meoni, LA, et al. A genome-wide admixture scan identifies MYH9 as a candidate locus associated with non-diabetic end stage renal disease in African Americans. Nat Genet 40 (2008), 1185–1192.
153. Roadmap Epigenomics Consortium, Kundaje, A, Meuleman, W, et al. Integrative analysis of 111 reference human epigenomes. Nature 518 (2015), 317–330.
154. Suhre, K, Shin, SY, Petersen, AK, et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 477 (2011), 54–60.
155. Rhee, EP, Ho, JE, Chen, MH, et al. A genome-wide association study of the human metabolome in a community-based cohort. Cell Metab 18 (2013), 130–143.
156. Suhre, K, Arnold, M, Bhagwat, AM, et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat Commun, 8, 2017, 14357.
157. GTEx Portal. http://www.gtexportal.org/home/ (accessed Oct 10, 2016).
158. Nelson, MR, Tipney, H, Painter, JL, et al. The support of human genetic evidence for approved drug indications. Nat Genet 47 (2015), 856–860.
159. Kiryluk, K, Li, Y, Scolari, F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46 (2014), 1187–1196.
160. Thomson, R, Genovese, G, Canon, C, et al. Evolution of the primate trypanolytic factor APOL1. Proc Natl Acad Sci USA 111 (2014), E2130–E2139.
161. McKnight, AJ, McKay, GJ, Maxwell, AP, Genetic and epigenetic risk factors for diabetic kidney disease. Adv Chronic Kidney Dis 21 (2014), 287–296.
162. Harjutsalo, V, Groop, PH, Epidemiology and risk factors for diabetic kidney disease. Adv Chronic Kidney Dis 21 (2014), 260–266.
163. Nanayakkara, S, Senevirathna, ST, Abeysekera, T, et al. An integrative study of the genetic, social and environmental determinants of chronic kidney disease characterized by tubulointerstitial damages in the north central region of Sri Lanka. J Occup Health 56 (2014), 28–38.
164. Batuman, V, Fifty years of Balkan endemic nephropathy: daunting questions, elusive answers. Kidney Int 69 (2006), 644–646.
165. Lunyera, J, Mohottige, D, Von Isenburg, M, Jeuland, M, Patel, UD, Stanifer, JW, CKD of uncertain etiology: a systematic review. Clin J Am Soc Nephrol 11 (2016), 379–385.
166. Sekula, P, Li, Y, Stanescu, HC, et al. Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies. Nephrol Dial Transplant, 2016, 10.1093/ndt/gfw001 Feb 4.
167. Titze, S, Schmid, M, Kottgen, A, et al., for the GCKD study investigators. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant 30 (2015), 441–451.
168. Fogo, A, WCN 2015 Renal Biopsy Histology Procedure Manual (in EN, ES, FR & RU). http://www.theisn.org/education/education-topics/pathology-topics/item/1720-wcn-2015-histology-procedure-manual (accessed Oct 1, 2016).
169. Haas, M, A reevaluation of routine electron microscopy in the examination of native renal biopsies. J Am Soc Nephrol 8 (1997), 70–76.
170. Chang, A, Gibson, IW, Cohen, AH, et al. A position paper on standardizing the non-neoplastic kidney biopsy report. Clin J Am Soc Nephrol 7 (2012), 1365–1368.
171. Lopez-Giacoman, S, Madero, M, Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J Nephrol 4 (2015), 57–73.
172. Devarajan, P, The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis 17 (2010), 469–479.
173. Colbert, G, Jain, N, de Lemos, JA, Hedayati, SS, Utility of traditional circulating and imaging-based cardiac biomarkers in patients with predialysis CKD. Clin J Am Soc Nephrol 10 (2015), 515–529.
174. Schanstra, JP, Zurbig, P, Alkhalaf, A, et al. Diagnosis and prediction of CKD progression by assessment of urinary peptides. J Am Soc Nephrology 26 (2015), 1999–2010.
175. Levin, A, Rigatto, C, Barrett, B, et al. Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort. Nephrol Dial Transplant 29 (2014), 1037–1047.
176. Fassett, RG, Venuthurupalli, SK, Gobe, GC, Coombes, JS, Cooper, MA, Hoy, WE, Biomarkers in chronic kidney disease: a review. Kidney Int 80 (2011), 806–821.
177. Gansevoort, RT, Correa-Rotter, R, Hemmelgarn, BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382 (2013), 339–352.
178. Schiffer, E, Liabeuf, S, Lacroix, C, et al. Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. J Hypertens 29 (2011), 783–790.
179. Kadatz, MJ, Lee, ES, Levin, A, Predicting progression in CKD: perspectives and precautions. Am J Kidney Dis 67 (2016), 779–786.
180. Sun, J, Axelsson, J, Machowska, A, et al. Biomarkers of cardiovascular disease and mortality risk in patients with advanced CKD. Clin J Am Soc Nephrol 11 (2016), 1163–1172.
181. Cisek, K, Krochmal, M, Klein, J, Mischak, H, The application of multi-omics and systems biology to identify therapeutic targets in chronic kidney disease. Nephrol Dial Transplant 31 (2015), 2003–2011.
182. Lv, J, Ehteshami, P, Sarnak, MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 185 (2013), 949–957.
183. Lv, J, Neal, B, Ehteshami, P, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med, 9, 2012, e1001293.
184. Perkovic, V, Verdon, C, Ninomiya, T, et al. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med, 5, 2008, e207.
185. Xie, X, Liu, Y, Perkovic, V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 67 (2016), 728–741.
186. Hou, W, Lv, J, Perkovic, V, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J 34 (2013), 1807–1817.
187. Baigent, C, Landray, MJ, Reith, C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377 (2011), 2181–2192.
188. DCCT/EDIC Research Group, de Boer, IH, Sun, W, et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 365 (2011), 2366–2376.
189. Wong, MG, Perkovic, V, Chalmers, J, et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39 (2016), 694–700.
190. Wanner, C, Inzucchi, SE, Lachin, JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
191. Heerspink, HJ, Desai, M, Jardine, M, Balis, D, Meininger, G, Perkovic, V, Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28 (2017), 368–375.
192. Zinman, B, Wanner, C, Lachin, JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
193. Tonelli, M, Gill, J, Pandeya, S, Bohm, C, Levin, A, Kiberd, BA, Barriers to blood pressure control and angiotensin enzyme inhibitor use in Canadian patients with chronic renal insufficiency. Nephrol Dial Transplant 17 (2002), 1426–1433.
194. Benner, JS, Glynn, RJ, Mogun, H, Neumann, PJ, Weinstein, MC, Avorn, J, Long-term persistence in use of statin therapy in elderly patients. JAMA 288 (2002), 455–461.
195. Razavian, M, Heeley, EL, Perkovic, V, et al. Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). Nephrol Dial Transplant 27 (2012), 1396–1402.
196. Ennis, J, Gillen, D, Rubenstein, A, et al. Clinical decision support improves physician guideline adherence for laboratory monitoring of chronic kidney disease: a matched cohort study. BMC Nephrol, 16, 2015, 163.
197. Elliott, MJ, Gil, S, Hemmelgarn, BR, et al. A scoping review of adult chronic kidney disease clinical pathways for primary care. Nephrol Dial Transplant, 2016, 10.1093/ndt/gfw208 published online Jun 2.
198. Galbraith, L, Jacobs, C, Hemmelgarn, BR, Donald, M, Manns, B, Jun, M, Chronic disease management interventions for people with chronic kidney disease in primary care: a systematic review and meta-analysis. Nephrol Dial Transplant, 2017, 10.1093/ndt/gfw359 published online Jan 16.
199. WHO. WHO model lists of essential medicines. http://www.who.int/medicines/publications/essentialmedicines/en/ (accessed Oct 10, 2016).
200. Manns, B, Hemmelgarn, B, Lillie, E, et al. Setting research priorities for patients on or nearing dialysis. Clin J Am Soc Nephrol 9 (2014), 1813–1821.
201. Tonelli, M, The roads less traveled? Diverging research and clinical priorities for dialysis patients and those with less severe CKD. Am J Kidney Dis 63 (2014), 124–132.
202. Tonelli, M, Karumanchi, SA, Thadhani, R, Epidemiology and mechanisms of uremia-related cardiovascular disease. Circulation 133 (2016), 518–536.
203. Ketteler, M, Elder, GJ, Evenepoel, P, et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 87 (2015), 502–528.
204. Levin, NW, Kotanko, P, Eckardt, KU, et al. Blood pressure in chronic kidney disease stage 5D—report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 77 (2010), 273–284.
205. Kidney disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 4 (2012), 1–335.
206. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl, 2009, S1–S130.
207. Davison, SN, Jassal, SV, Supportive care: integration of patient-centered kidney care to manage symptoms and geriatric syndromes. Clin J Am Soc Nephrol, 2016, 10.2215/CJN.01050116 published online Aug 10.
208. Herzog, CA, Asinger, RW, Berger, AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80 (2011), 572–586.
209. Roberts, MA, Pilmore, HL, Ierino, FL, et al. The rationale and design of the beta-blocker to lower cardiovascular dialysis events (BLOCADE) feasibility study. Nephrology (Carlton) 20 (2015), 140–147.
210. Heerspink, HJL, Ninomiya, T, Zoungas, S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 373 (2009), 1009–1015.
211. Palmer, SC, Navaneethan, SD, Craig, JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev, 5, 2014 CD007784.
212. Ruggenenti, P, Porrini, E, Motterlini, N, et al. Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol 23 (2012), 1717–1724.
213. Cice, G, Di Benedetto, A, D'Isa, S, et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure: a double-blind, placebo-controlled trial. J Am Coll Cardiol 56 (2010), 1701–1708.
214. Johnson, RJ, Nakagawa, T, Jalal, D, Sánchez-Lozada, LG, Kang, DH, Ritz, E, Uric acid and chronic kidney disease: which is chasing which?. Nephrol Dial Transplant 28 (2013), 2221–2228.
215. Palmer, SC, Sciancalepore, M, Strippoli, GFM, Trial quality in nephrology: how are we measuring up?. Am J Kidney Dis 58 (2011), 335–337.
216. Inrig, JK, Califf, RM, Tasneem, A, et al. The landscape of clinical trials in nephrology: a systematic review of ClinicalTrials.gov. Am J Kidney Dis 63 (2014), 771–780.
217. Levey, AS, Inker, LA, Matsushita, K, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 64 (2014), 821–835.
218. Inker, LA, Levey, AS, Pandya, K, et al. Early change in proteinuria as a surrogate endpoint for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis 64 (2014), 74–85.
219. Heerspink, HJL, Kröpelin, TF, Hoekman, J, de Zeeuw, D, reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol 26 (2015), 2055–2064.
220. FDA. Qualification of biomarker—total kidney volume in studies for treatments of autosomal dominant polycystic kidney disease: guidance for industry. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM458483.pdf (accessed Sept 28, 2016).
221. Tong, A, Manns, B, Hemmelgarn, B, et al. Establishing core outcome domains in hemodialysis: report of the Standardised Outcomes in Nephrology-Hemodialysis (SONG-HD) consensus workshops. Am J Kidney Dis 69 (2017), 97–107.
222. Tong, A, Crowe, S, Chando, S, et al. Research priorities in CKD: report of a national workshop conducted in Australia. Am J Kidney Dis 66 (2015), 212–222.
223. Hatfield, I, Allison, A, Flight, L, Julious, SA, Dimairo, M, Adaptive designs undertaken in clinical research: a review of registered clinical trials. Trials, 17, 2016, 150.
224. Bhatt, DL, Mehta, C, Adaptive designs for clinical trials. N Engl J Med 375 (2016), 65–74.
225. Antman, EM, Loscalzo, J, Precision medicine in cardiology. Nat Rev Cardiol 13 (2016), 591–602.
226. US Food and Drug Administration. Guidance for industry. Enrichment strategies for clinical trials to support approval of human drugs and biological products. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332181.pdf, December, 2012 (accessed March 24, 2017).
227. Ravindran, S, Kuruvilla, V, Wilbur, K, Munusamy, S, Nephroprotective effects of metformin in diabetic nephropathy. J Cell Physiol 232 (2017), 731–742.